source
stringlengths 2
222
| date
stringlengths 19
19
| url
stringlengths 22
853
⌀ | text
stringlengths 0
10k
⌀ | title
stringlengths 0
701
| context_id
stringlengths 1
9
| document_id
stringclasses 2
values | document_type
stringclasses 2
values |
|---|---|---|---|---|---|---|---|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-05-09 09:05:00
| null |
WESTON, FLA., MAY 09, 2023 (GLOBE NEWSWIRE) -- ZYVERSA THERAPEUTICS, INC. (NASDAQ: ZVSA, OR “ZYVERSA”), A CLINICAL STAGE SPECIALTY BIOPHARMACEUTICAL COMPANY DEVELOPING FIRST-IN-CLASS DRUGS FOR THE TREATMENT OF RENAL AND INFLAMMATORY DISEASES WITH HIGH UNMET MEDICAL NEEDS, ANNOUNCES THAT STEPHEN C. GLOVER, CO-FOUNDER, CHAIRMAN, CHIEF EXECUTIVE OFFICER, AND PRESIDENT, WILL PARTICIPATE IN THE 2023 BIO INTERNATIONAL CONVENTION BEING HELD JUNE 5 - 8, 2023 IN BOSTON, MASSACHUSETTS.
|
ZYVERSA THERAPEUTICS' CEO, STEPHEN C. GLOVER, TO PARTICIPATE IN THE 2023 BIO INTERNATIONAL CONVENTION
|
ZVSA
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-05-04 09:07:00
| null |
WESTON, FLA., MAY 04, 2023 (GLOBE NEWSWIRE) -- ZYVERSA THERAPEUTICS, INC. (NASDAQ: ZVSA, OR “ZYVERSA”), A CLINICAL STAGE SPECIALTY BIOPHARMACEUTICAL COMPANY DEVELOPING FIRST-IN-CLASS DRUGS FOR TREATMENT OF INFLAMMATORY AND RENAL DISEASES, ANNOUNCES PUBLICATION OF AN ARTICLE IN THE PEER-REVIEWED JOURNAL, HEPATOLOGY, SUPPORTING THE CRITICAL ROLE OF EXTRACELLULAR ASC SPECKS IN PROPAGATING DAMAGING LIVER INFLAMMATION IN AH.
|
ZYVERSA THERAPEUTICS ANNOUNCES A PUBLICATION IN HEPATOLOGY REVEALING THAT ALCOHOL-INDUCED EXTRACELLULAR ASC SPECKS PERPETUATE LIVER INFLAMMATION AND DAMAGE IN ALCOHOLIC HEPATITIS
|
ZVSA
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-05-01 18:30:00
| null |
WESTON, FLA., MAY 01, 2023 (GLOBE NEWSWIRE) -- ZYVERSA THERAPEUTICS, INC. (NASDAQ: ZVSA, OR “ZYVERSA”), A CLINICAL STAGE SPECIALTY BIOPHARMACEUTICAL COMPANY DEVELOPING FIRST-IN-CLASS DRUGS FOR TREATMENT OF INFLAMMATORY AND RENAL DISEASES, ANNOUNCES CLOSING ON APRIL 28, 2023 OF ITS PREVIOUSLY ANNOUNCED “REASONABLE BEST EFFORTS” PUBLIC OFFERING OF 11,015,500 SHARES OF COMMON STOCK (OR COMMON STOCK EQUIVALENTS IN LIEU THEREOF) AND WARRANTS TO PURCHASE UP TO 11,015,500 SHARES OF COMMON STOCK AT AN EFFECTIVE COMBINED PRICE OF $1.00 PER SHARE AND COMMON WARRANT FOR AGGREGATE GROSS PROCEEDS OF APPROXIMATELY $11.0 MILLION, BEFORE DEDUCTING PLACEMENT AGENT FEES AND OTHER OFFERING EXPENSES. THE WARRANTS WILL HAVE AN EXERCISE PRICE OF $1.00 PER SHARE, WILL BE EXERCISABLE IMMEDIATELY, AND WILL EXPIRE FIVE YEARS FROM THE INITIAL ISSUANCE DATE.
|
ZYVERSA THERAPEUTICS, INC. ANNOUNCES CLOSING OF $11.0 MILLION PUBLIC OFFERING
|
ZVSA
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-04-26 09:10:00
| null |
WESTON, FLA., APRIL 26, 2023 (GLOBE NEWSWIRE) -- ZYVERSA THERAPEUTICS, INC. (NASDAQ: ZVSA, OR “ZYVERSA”), A CLINICAL STAGE SPECIALTY BIOPHARMACEUTICAL COMPANY DEVELOPING FIRST-IN-CLASS DRUGS FOR TREATMENT OF INFLAMMATORY AND RENAL DISEASES, TODAY ANNOUNCED THE PRICING OF ITS “REASONABLE BEST EFFORTS” PUBLIC OFFERING OF 11,015,500 SHARES OF COMMON STOCK (OR COMMON STOCK EQUIVALENTS IN LIEU THEREOF) AND WARRANTS TO PURCHASE UP TO 11,015,500 SHARES OF COMMON STOCK AT AN EFFECTIVE COMBINED PRICE OF $1.00 PER SHARE AND COMMON WARRANT FOR AGGREGATE GROSS PROCEEDS OF APPROXIMATELY $11.0 MILLION, BEFORE DEDUCTING PLACEMENT AGENT FEES AND OTHER OFFERING EXPENSES. THE WARRANTS WILL HAVE AN EXERCISE PRICE OF $1.00 PER SHARE, WILL BE EXERCISABLE IMMEDIATELY, AND WILL EXPIRE FIVE YEARS FROM THE INITIAL ISSUANCE DATE.
|
ZYVERSA THERAPEUTICS, INC. ANNOUNCES PRICING OF $11.0 MILLION PUBLIC OFFERING
|
ZVSA
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-04-25 09:07:00
| null |
WESTON, FLA., APRIL 25, 2023 (GLOBE NEWSWIRE) -- ZYVERSA THERAPEUTICS, INC. (NASDAQ: ZVSA, OR “ZYVERSA”), A CLINICAL STAGE SPECIALTY BIOPHARMACEUTICAL COMPANY DEVELOPING FIRST-IN-CLASS DRUGS FOR TREATMENT OF INFLAMMATORY AND RENAL DISEASES, ANNOUNCES PUBLICATION OF AN ARTICLE IN THE PEER-REVIEWED JOURNAL OF NEUROINFLAMMATION SUPPORTING THE POTENTIAL OF ASC SPECKS AS A THERAPEUTIC TARGET FOR PARKINSON'S DISEASE.
|
ZYVERSA THERAPEUTICS ANNOUNCES PUBLICATION OF AN ARTICLE IN THE JOURNAL OF NEUROINFLAMMATION ADDRESSING THE ROLE OF ASC SPECKS IN PROPAGATION OF ALPHA-SYNUCLEIN PATHOLOGY IN PARKINSON'S DISEASE
|
ZVSA
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-04-24 09:07:00
| null |
WESTON, FLA., APRIL 24, 2023 (GLOBE NEWSWIRE) -- ZYVERSA THERAPEUTICS, INC. (NASDAQ: ZVSA; “ZYVERSA”), A CLINICAL STAGE SPECIALTY BIOPHARMACEUTICAL COMPANY DEVELOPING FIRST-IN-CLASS DRUGS FOR TREATMENT OF PATIENTS WITH RENAL AND INFLAMMATORY DISEASES WHO HAVE UNMET MEDICAL NEEDS, ANNOUNCES THAT INTERNATIONALLY RECOGNIZED AUTHORITY IN THE FIELD OF INNATE IMMUNITY, DR. DOUGLAS GOLENBOCK, HAS JOINED ZYVERSA'S INFLAMMATORY DISEASE SCIENTIFIC ADVISORY BOARD.
|
ZYVERSA THERAPEUTICS ADDS DR. DOUGLAS GOLENBOCK TO ITS INFLAMMATORY DISEASE SCIENTIFIC ADVISORY BOARD TO SUPPORT ADVANCEMENT OF INFLAMMASOME ASC INHIBITOR IC 100
|
ZVSA
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-04-19 09:07:00
| null |
WESTON, FLA., APRIL 19, 2023 (GLOBE NEWSWIRE) -- ZYVERSA THERAPEUTICS, INC. (NASDAQ: ZVSA, OR “ZYVERSA”), A CLINICAL STAGE SPECIALTY BIOPHARMACEUTICAL COMPANY DEVELOPING FIRST-IN-CLASS DRUGS FOR TREATMENT OF INFLAMMATORY AND RENAL DISEASES, IS PLEASED TO ANNOUNCE THAT WORLD RENOWNED INFLAMMASOME RESEARCHERS AND INVENTORS OF ZYVERSA'S INFLAMMASOME ASC INHIBITOR IC 100 FROM THE UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE HAVE PUBLISHED A SCIENTIFIC PAPER IN THE PEER-REVIEWED JOURNAL, BIOMATERIALS.
|
ZYVERSA THERAPEUTICS ANNOUNCES ARTICLE PUBLISHED IN BIOMATERIALS ADDRESSING THE CRITICAL ROLE OF INFLAMMASOME ACTIVATION IN NEUROINFLAMMATION RESULTING FROM INTRACORTICAL IMPLANTS
|
ZVSA
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-04-13 09:07:00
| null |
WESTON, FLA., APRIL 13, 2023 (GLOBE NEWSWIRE) -- ZYVERSA THERAPEUTICS, INC. (NASDAQ: ZVSA, OR “ZYVERSA”), A CLINICAL STAGE SPECIALTY BIOPHARMACEUTICAL COMPANY DEVELOPING FIRST-IN-CLASS DRUGS FOR TREATMENT OF INFLAMMATORY AND RENAL DISEASES, ANNOUNCES PUBLICATION OF A REVIEW ARTICLE IN FRONTIERS IN PHARMACOLOGY ADDRESSING THE NLRP3 INFLAMMASOME PATHWAY AS A POTENTIAL DRUG TARGET FOR TREATING MILD COGNITIVE IMPAIRMENT (“MCI”) AND AD.
|
ZYVERSA THERAPEUTICS ANNOUNCES REVIEW ARTICLE PUBLISHED IN FRONTIERS IN PHARMACOLOGY ADDRESSING MICROGLIAL INFLAMMATORY ACTIVITY AS A PHARMACOLOGICAL TARGET IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE
|
ZVSA
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-04-12 09:07:00
| null |
WESTON, FLA., APRIL 12, 2023 (GLOBE NEWSWIRE) -- ZYVERSA THERAPEUTICS, INC. (NASDAQ: ZVSA, OR “ZYVERSA”), A CLINICAL STAGE SPECIALTY BIOPHARMACEUTICAL COMPANY DEVELOPING FIRST-IN-CLASS DRUGS FOR THE TREATMENT OF RENAL AND INFLAMMATORY DISEASES WITH HIGH UNMET MEDICAL NEEDS, ANNOUNCES THAT STEPHEN C. GLOVER, CO-FOUNDER, CHAIRMAN, CHIEF EXECUTIVE OFFICER, AND PRESIDENT, WILL APPEAR ON BENZINGA ALL ACCESS ON APRIL 18, 2023.
|
ZYVERSA THERAPEUTICS' CEO, STEPHEN C. GLOVER TO APPEAR ON BENZINGA 'ALL ACCESS'
|
ZVSA
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-04-10 09:07:00
| null |
WESTON, FLA., APRIL 10, 2023 (GLOBE NEWSWIRE) -- ZYVERSA THERAPEUTICS, INC. (NASDAQ: ZVSA, OR “ZYVERSA”), A CLINICAL STAGE SPECIALTY BIOPHARMACEUTICAL COMPANY DEVELOPING FIRST-IN-CLASS DRUGS FOR TREATMENT OF INFLAMMATORY AND RENAL DISEASES, IS PLEASED TO ANNOUNCE THAT WORLD RENOWNED INFLAMMASOME RESEARCHERS AND INVENTORS OF ZYVERSA'S INFLAMMASOME ASC INHIBITOR IC 100 HAVE PUBLISHED A SCIENTIFIC PAPER IN THE PEER-REVIEWED JOURNAL, BRAIN PATHOLOGY. THE RESEARCHERS ARE FROM THE UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE.
|
ZYVERSA THERAPEUTICS ANNOUNCES ARTICLE PUBLISHED IN BRAIN PATHOLOGY ADDRESSING INFLAMMASOME SIGNALING PROTEINS IN ALZHEIMER'S DISEASE
|
ZVSA
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-04-03 09:05:00
| null |
KEY HIGHLIGHTS:
|
ZYVERSA THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR-END 2022 CORPORATE AND FINANCIAL RESULTS
|
ZVSA
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-03-13 16:30:00
| null |
WESTON, FLA., MARCH 13, 2023 (GLOBE NEWSWIRE) -- ZYVERSA THERAPEUTICS, INC. (NASDAQ: ZVSA, OR “ZYVERSA”), A CLINICAL-STAGE SPECIALTY BIOPHARMACEUTICAL COMPANY DEVELOPING FIRST-IN-CLASS DRUGS FOR TREATMENT OF RENAL AND INFLAMMATORY DISEASES WITH HIGH UNMET MEDICAL NEEDS, TODAY ANNOUNCED THE GRANT OF INDUCEMENT EQUITY AWARDS TO TWO NEW EMPLOYEES. THE GRANTS WERE APPROVED BY THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS, EFFECTIVE AS OF MARCH 8, 2023, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).
|
ZYVERSA THERAPEUTICS REPORTS NEW EMPLOYMENT INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
|
ZVSA
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-03-07 09:20:00
| null |
WESTON, FLA., MARCH 07, 2023 (GLOBE NEWSWIRE) -- ZYVERSA THERAPEUTICS, INC. (NASDAQ: ZVSA; “ZYVERSA”), A CLINICAL STAGE SPECIALTY BIOPHARMACEUTICAL COMPANY DEVELOPING FIRST-IN-CLASS DRUGS FOR TREATMENT OF PATIENTS WITH RENAL AND INFLAMMATORY DISEASES WHO HAVE UNMET MEDICAL NEEDS, ANNOUNCES THAT DR. RICHARD J. GLASSOCK HAS JOINED ZYVERSA'S RENAL SCIENTIFIC ADVISORY BOARD.
|
ZYVERSA THERAPEUTICS ADDS DR. RICHARD J. GLASSOCK TO ITS RENAL SCIENTIFIC ADVISORY BOARD TO SUPPORT CLINICAL ADVANCEMENT OF RENAL CHOLESTEROL EFFLUX MEDIATOR™ VAR 200
|
ZVSA
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-03-01 09:20:00
| null |
WESTON, FLA., MARCH 01, 2023 (GLOBE NEWSWIRE) -- ZYVERSA THERAPEUTICS, INC. (NASDAQ: ZVSA, OR “ZYVERSA”), A CLINICAL STAGE SPECIALTY BIOPHARMACEUTICAL COMPANY DEVELOPING FIRST-IN-CLASS DRUGS FOR THE TREATMENT OF INFLAMMATORY AND RENAL DISEASES WITH HIGH UNMET MEDICAL NEEDS, ANNOUNCED TODAY THAT STEPHEN C. GLOVER, CO-FOUNDER, CHAIRMAN, CHIEF EXECUTIVE OFFICER, AND PRESIDENT WILL PARTICIPATE IN A FIRESIDE CHAT AT THE 33RD ANNUAL OPPENHEIMER HEALTHCARE CONFERENCE TO BE HELD VIRTUALLY MARCH 13-15.
|
ZYVERSA THERAPEUTICS TO PARTICIPATE IN A FIRESIDE CHAT AT OPPENHEIMER HEALTHCARE CONFERENCE
|
ZVSA
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-02-27 09:20:00
| null |
WESTON, FLA., FEB. 27, 2023 (GLOBE NEWSWIRE) -- ZYVERSA THERAPEUTICS, INC. (NASDAQ: ZVSA, OR “ZYVERSA”), A CLINICAL STAGE SPECIALTY BIOPHARMACEUTICAL COMPANY DEVELOPING FIRST-IN-CLASS DRUGS FOR THE TREATMENT OF INFLAMMATORY AND RENAL DISEASES WITH HIGH UNMET MEDICAL NEEDS, ANNOUNCED TODAY THAT STEPHEN C. GLOVER, CO-FOUNDER, CHAIRMAN, CHIEF EXECUTIVE OFFICER, AND PRESIDENT WILL PARTICIPATE IN A FIRESIDE CHAT AT THE 35TH ANNUAL ROTH CONFERENCE SCHEDULED FOR MARCH 12-14, 2023 TO BE HELD AT THE RITZ CARLTON, LAGUNA NIGUEL IN DANA POINT, CALIFORNIA.
|
ZYVERSA THERAPEUTICS TO PARTICIPATE IN A FIRESIDE CHAT AT ROTH ANNUAL CONFERENCE
|
ZVSA
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-02-23 09:20:00
| null |
WESTON, FLA., FEB. 23, 2023 (GLOBE NEWSWIRE) -- ZYVERSA THERAPEUTICS, INC. (NASDAQ: ZVSA, OR “ZYVERSA”), A CLINICAL STAGE SPECIALTY BIOPHARMACEUTICAL COMPANY DEVELOPING FIRST-IN-CLASS DRUGS FOR TREATMENT OF UNDERSERVED PATIENTS WITH INFLAMMATORY AND RENAL DISEASES, IS PLEASED TO ANNOUNCE THAT WORLD RENOWNED INFLAMMASOME RESEARCHERS FROM THE UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE HAVE PUBLISHED A SCIENTIFIC PAPER IN THE PEER-REVIEWED JOURNAL, TRANSLATIONAL RESEARCH. THE ARTICLE DEMONSTRATES THAT INFLAMMASOME ACTIVATION AND PYROPTOTIC RELEASE OF ACTIVE CYTOKINES AND ASC SPECKS FOLLOWING TBI IS SYNERGISTIC WITH INFLAMMASOME ACTIVATION THAT OCCURS IN AD, HEIGHTENING THE INFLAMMATORY RESPONSE AND WORSENING COGNITIVE OUTCOMES. FURTHERMORE, IT SHOWS THAT IC 100, AN INFLAMMASOME ASC INHIBITOR, REDUCES INFLAMMASOME ACTIVATION THAT TRIGGERS THE INFLAMMATORY RESPONSE. CLICK HERE TO READ THE ARTICLE.
|
ZYVERSA THERAPEUTICS ANNOUNCES NEW PUBLICATION IN TRANSLATIONAL RESEARCH SHOWING IC 100 REDUCES INFLAMMASOME ACTIVATION IN MOUSE MODEL FOR ALZHEIMER'S DISEASE FOLLOWING TRAUMATIC BRAIN INJURY
|
ZVSA
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-01-27 16:00:00
| null |
WESTON, FLA., JAN. 27, 2023 (GLOBE NEWSWIRE) -- ZYVERSA THERAPEUTICS, INC. (NASDAQ: ZVSA, OR “ZYVERSA”), A CLINICAL-STAGE SPECIALTY BIOPHARMACEUTICAL COMPANY DEVELOPING FIRST-IN-CLASS DRUGS FOR TREATMENT OF RENAL AND INFLAMMATORY DISEASES WITH HIGH UNMET MEDICAL NEEDS, TODAY ANNOUNCED THE GRANT OF AN INDUCEMENT EQUITY AWARD OUTSIDE ZYVERSA'S 2022 EQUITY INCENTIVE PLAN TO ITS NEWLY APPOINTED CHIEF MEDICAL OFFICER AND SENIOR VICE PRESIDENT OF MEDICAL AFFAIRS, DR. PABLO GUZMAN. THE GRANTS WERE APPROVED BY THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS, EFFECTIVE AS OF JANUARY 26, 2023, AS INDUCEMENTS MATERIAL TO DR. GUZMAN ENTERING INTO EMPLOYMENT WITH ZYVERSA IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).
|
ZYVERSA THERAPEUTICS REPORTS INDUCEMENT GRANT TO NEWLY APPOINTED CHIEF MEDICAL OFFICER UNDER NASDAQ LISTING RULE 5635(C)(4)
|
ZVSA
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-01-05 09:45:00
| null |
NEW APPOINTMENTS BRING EXPERTISE AND PROVEN LEADERSHIP TO ZYVERSA TO SUPPORT ADVANCEMENT AND DEVELOPMENT OF VAR 200 FOR RENAL DISEASE, AND IC 100 FOR INFLAMMATORY DISEASES WESTON, FLA. , JAN. 5, 2023 /PRNEWSWIRE/ -- ZYVERSA THERAPEUTICS, INC. (NASDAQ: ZVSA, OR "ZYVERSA"), A CLINICAL- STAGE SPECIALTY BIOPHARMACEUTICAL COMPANY DEVELOPING FIRST-IN-CLASS DRUGS FOR TREATMENT OF RENAL AND INFLAMMATORY DISEASES WITH HIGH UNMET MEDICAL NEEDS, ANNOUNCED TODAY THE APPOINTMENTS OF THREE NEW INDEPENDENT BOARD MEMBERS, BRINGING THE TOTAL BOARD MEMBERSHIP TO SEVEN.
|
ZYVERSA THERAPEUTICS APPOINTS THREE NEW BOARD MEMBERS
|
ZVSA
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-01-03 09:45:00
| null |
DRS. DANIEL C. CATTRAN AND FERNANDO C.
|
ZYVERSA THERAPEUTICS ADDS TWO ESTEEMED LEADERS IN NEPHROLOGY TO ITS RENAL SCIENTIFIC ADVISORY BOARD TO SUPPORT CLINICAL ADVANCEMENT OF LEAD RENAL DRUG CANDIDATE, VAR 200
|
ZVSA
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-12-20 09:45:00
| null |
ZYVERSA IS A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING FIRST-IN-CLASS PRODUCT CANDIDATES TO ADDRESS SIGNIFICANT UNMET MEDICAL NEEDS OF PATIENTS WITH INFLAMMATORY AND RENAL DISEASES LEAD ANTI-INFLAMMATORY PRODUCT CANDIDATE, INFLAMMASOME ASC INHIBITOR IC 100, BLOCKS INITIATION AND PERPETUATION OF DAMAGING INFLAMMATION THAT IS PATHOGENIC IN A MULTITUDE OF INFLAMMATORY DISEASES LEAD RENAL PRODUCT CANDIDATE, PHASE 2A-READY VAR 200, MEDIATES REMOVAL OF EXCESS INTRACELLULAR LIPIDS THAT CONTRIBUTE TO KIDNEY DAMAGE LEADING TO END-STAGE RENAL DISEASE WESTON, FLA. , DEC. 20, 2022 /PRNEWSWIRE/ -- ZYVERSA THERAPEUTICS, INC. (NASDAQ: ZVSA; "ZYVERSA"), A CLINICAL STAGE SPECIALTY BIOPHARMACEUTICAL COMPANY DEVELOPING FIRST-IN-CLASS DRUGS FOR TREATMENT OF INFLAMMATORY AND RENAL DISEASES, IS PLEASED TO ANNOUNCE THAT STEPHEN C.
|
ZYVERSA THERAPEUTICS' CEO, STEPHEN C. GLOVER, TO PARTICIPATE IN THE 41ST ANNUAL J.P.
|
ZVSA
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-12-12 21:05:00
| null |
ZYVERSA IS A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING FIRST-IN-CLASS PRODUCT CANDIDATES FOR TREATMENT OF RENAL AND INFLAMMATORY DISEASES WESTON, FLA. AND BRIDGEWATER, N.J.
|
ZYVERSA THERAPEUTICS INC. AND LARKSPUR HEALTH ACQUISITION CORP. CLOSE BUSINESS COMBINATION; ZYVERSA EXPECTED TO BEGIN TRADING ON NASDAQ DECEMBER 13, 2022 (TICKER "ZVSA")
|
ZVSA
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-28 07:05:00
| null |
MR. GLOVER WILL BE JOINING FOUR OTHER LIFE SCIENCE EXECUTIVES IN A GENERAL SESSION TITLED, CEO PANEL: LEARN FROM THE EXPERTS ZYVERSA IS A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY WITH TWO LICENSED PROPRIETARY PRODUCT PLATFORMS TARGETING RENAL AND INFLAMMATORY DISEASES ZYVERSA AND LARKSPUR HEALTH ENTERED INTO A DEFINITIVE BUSINESS COMBINATION AGREEMENT ON JULY 20, 2022, WHICH IS EXPECTED TO BE COMPLETED IN FOURTH QUARTER OF 2022 COMBINED COMPANY EXPECTED TO BE NAMED ZYVERSA THERAPEUTICS, INC. AND LISTED ON NASDAQ UNDER TICKER "ZVSA" WESTON, FLA. AND BRIDGEWATER, N.J.
|
ZYVERSA THERAPEUTICS' CEO, STEPHEN C. GLOVER, IS INVITED SPEAKER AT BIOFLORIDA 2022 ANNUAL CONFERENCE
|
ZVSA
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-09-27 13:00:00
| null |
AGGREGATE COMMITTED FINANCING IN SUPPORT OF THE BUSINESS COMBINATION NOW AT $10.0 MILLION ZYVERSA AND LARKSPUR ENTERED INTO A DEFINITIVE BUSINESS COMBINATION AGREEMENT ON JULY 20, 2022 ZYVERSA IS A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING FIRST-IN-CLASS PRODUCT CANDIDATES TO ADDRESS SIGNIFICANT UNMET MEDICAL NEEDS IN PATIENTS WITH RENAL AND INFLAMMATORY DISEASES TRANSACTION EXPECTED TO BE COMPLETED IN FOURTH QUARTER OF 2022 COMBINED COMPANY EXPECTED TO BE NAMED ZYVERSA THERAPEUTICS, INC. AND LISTED ON NASDAQ UNDER TICKER "ZVSA" BRIDGEWATER, N.J. AND WESTON, FLA.
|
ZYVERSA THERAPEUTICS AND LARKSPUR HEALTH ACQUISITION CORP. ANNOUNCE BUSINESS COMBINATION, INTERIM FINANCING AND PIPE INVESTMENT UPDATE
|
ZVSA
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-08-22 08:05:00
| null |
AGE-RELATED CHRONIC INFLAMMATION INDUCED BY ACTIVATION OF NLRP1 INFLAMMASOMES IS IMPLICATED IN DEVELOPMENT AND PROGRESSION OF NEURODEGENERATIVE DISEASES SUCH AS ALZHEIMER'S AND PARKINSON'S DISEASES IC 100 RESEARCH WAS CONDUCTED AT THE UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE BY ACCLAIMED EXPERTS IN IMMUNOLOGY, AND LEADERS AT THE FOREFRONT OF INFLAMMASOME RESEARCH IC 100, A NOVEL MONOCLONAL ANTIBODY INFLAMMASOME ASC INHIBITOR, TARGETS MULTIPLE TYPES OF INFLAMMASOMES, INCLUDING NLRP1, TO BLOCK INITIATION AND PERPETUATION OF DAMAGING CHRONIC INFLAMMATION WESTON, FLA. AND BRIDGEWATER, N.J.
|
DATA PUBLISHED IN FRONTIERS IN MOLECULAR NEUROSCIENCE DEMONSTRATE THAT ZYVERSA'S INFLAMMASOME ASC INHIBITOR, IC 100, IS EFFECTIVE IN REDUCING BRAIN INFLAMMATION IN A PRECLINICAL MODEL OF AGING
|
ZVSA
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-03-16 17:00:00
| null |
NEW YORK, MARCH 16, 2021 (GLOBE NEWSWIRE) -- Z-WORK ACQUISITION CORP. (NASDAQ: ZWRKU) (THE “COMPANY”) ANNOUNCED THAT COMMENCING MARCH 22, 2021, HOLDERS OF THE UNITS SOLD IN THE COMPANY'S INITIAL PUBLIC OFFERING OF 23,000,000 UNITS, COMPLETED ON FEBRUARY 2, 2021, MAY ELECT TO SEPARATELY TRADE THE CLASS A COMMON STOCK AND WARRANTS INCLUDED IN THE UNITS. THE CLASS A COMMON STOCK AND WARRANTS THAT ARE SEPARATED WILL TRADE ON THE NASDAQ STOCK MARKET UNDER THE SYMBOLS “ZWRK” AND “ZWRKW,” RESPECTIVELY. THOSE UNITS NOT SEPARATED WILL CONTINUE TO TRADE ON THE NASDAQ STOCK MARKET UNDER THE SYMBOL “ZWRKU.” NO FRACTIONAL WARRANTS WILL BE ISSUED UPON SEPARATION OF THE UNITS AND ONLY WHOLE WARRANTS WILL TRADE. HOLDERS OF UNITS WILL NEED TO HAVE THEIR BROKERS CONTACT CONTINENTAL STOCK TRANSFER & TRUST COMPANY, THE COMPANY'S TRANSFER AGENT, IN ORDER TO SEPARATE THE UNITS INTO CLASS A COMMON STOCK AND WARRANTS.
|
Z-WORK ACQUISITION CORP. ANNOUNCES THE SEPARATE TRADING OF ITS CLASS A COMMON STOCK AND WARRANTS, COMMENCING MARCH 22, 2021
|
ZWRKU
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-07-20 13:30:00
| null |
MILWAUKEE--(BUSINESS WIRE)--ZURN ELKAY WATER SOLUTIONS DECLARES QUARTERLY CASH DIVIDEND.
|
ZURN ELKAY WATER SOLUTIONS DECLARES QUARTERLY CASH DIVIDEND
|
ZWS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-07-18 08:30:00
| null |
SUSTAINABILITY LINKED DEPOSITS (SLD) REWARD BUSINESS ACCOUNT HOLDERS WHO ACHIEVE PREDETERMINED SUSTAINABILITY TARGETS SLDS JOIN A SUITE OF OPTIONS OFFERED BY BMO TO HELP BUSINESS CLIENTS MAKE PROGRESS ON THEIR SUSTAINABILITY GOALS TORONTO , JULY 18, 2023 /PRNEWSWIRE/ - BMO (TSX: BMO) (NYSE: BMO) TODAY ANNOUNCED IT IS PROVIDING ITS INNOVATIVE NEW SUSTAINABILITY-LINKED DEPOSIT (SLD) PRODUCT TO ZURN ELKAY WATER SOLUTIONS (NYSE: ZWS), A CLIENT AND LEADING ENGINEERED WATER SOLUTIONS COMPANY. A SUSTAINABILITY-LINKED DEPOSIT LINKS THE INTEREST PAID ON A DEPOSIT ACCOUNT TO A CLIENT'S ACHIEVEMENT OF DEFINED SUSTAINABILITY TARGETS.
|
BMO PROVIDES INNOVATIVE NEW SUSTAINABILITY-LINKED DEPOSIT PRODUCT TO ZURN ELKAY WATER SOLUTIONS
|
ZWS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-05-04 13:53:00
| null |
MILWAUKEE--(BUSINESS WIRE)--ZURN ELKAY WATER SOLUTIONS DECLARES QUARTERLY CASH DIVIDEND.
|
ZURN ELKAY WATER SOLUTIONS DECLARES QUARTERLY CASH DIVIDEND
|
ZWS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-03-15 16:21:00
| null |
MILWAUKEE--(BUSINESS WIRE)--ZURN ELKAY WATER SOLUTIONS CORPORATION (NYSE: ZWS) ANNOUNCED TODAY THAT EMMA MCTAGUE, 49, SENIOR VICE PRESIDENT AND CHIEF HUMAN RESOURCES OFFICER OF OSHKOSH CORPORATION, HAS JOINED THE COMPANY'S BOARD OF DIRECTORS EFFECTIVE MARCH 15. “WE ARE THRILLED TO ADD EMMA TO THE ZURN ELKAY BOARD OF DIRECTORS,” SAID TODD A. ADAMS, ZURN ELKAY CHAIRMAN AND CEO.
|
ZURN ELKAY WATER SOLUTIONS ADDS EMMA MCTAGUE TO BOARD OF DIRECTORS
|
ZWS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-02-20 11:58:00
| null |
MILWAUKEE--(BUSINESS WIRE)-- #ESG--ZURN ELKAY WATER SOLUTIONS CORPORATION (NYSE: ZWS) PUBLISHED ITS 2022 SUSTAINABILITY REPORT.
|
ZURN ELKAY WATER SOLUTIONS PUBLISHES 2022 SUSTAINABILITY REPORT; PRODUCT DONATIONS PROVIDE SAFER DRINKING WATER FOR SCHOOL CHILDREN
|
ZWS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-02-07 16:09:00
| null |
MILWAUKEE, WIS.
|
ZURN ELKAY WATER SOLUTIONS REPORTS FOURTH QUARTER 2022 FINANCIAL RESULTS
|
ZWS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-02-01 19:45:00
| null |
MILWAUKEE--( BUSINESS WIRE )--ZURN ELKAY WATER SOLUTIONS CORPORATION (NYSE: ZWS) ANNOUNCED TODAY THAT ITS BOARD OF DIRECTORS DECLARED A QUARTERLY COMMON STOCK DIVIDEND OF $0.07 PER SHARE PAYABLE IN CASH ON MARCH 7, 2023 TO STOCKHOLDERS OF RECORD AS OF FEBRUARY 21, 2023.
|
ZURN ELKAY WATER SOLUTIONS DECLARES QUARTERLY CASH DIVIDEND
|
ZWS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-12-20 18:13:00
| null |
MILWAUKEE--( BUSINESS WIRE )--ZURN ELKAY WATER SOLUTIONS (NYSE: ZWS) WAS NAMED BY NEWSWEEK AND STATISTA AS ONE OF AMERICA'S MOST RESPONSIBLE COMPANIES 2023.
|
ZURN ELKAY WATER SOLUTIONS NAMED TO NEWSWEEK'S 2023 LIST OF AMERICA'S MOST RESPONSIBLE COMPANIES
|
ZWS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-28 16:09:00
| null |
MILWAUKEE--(BUSINESS WIRE)--ZURN ELKAY WATER SOLUTIONS TO PARTICIPATE IN BAIRD 2022 GLOBAL INDUSTRIAL CONFERENCE
|
ZURN ELKAY WATER SOLUTIONS TO PARTICIPATE IN BAIRD 2022 GLOBAL INDUSTRIAL CONFERENCE
|
ZWS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-25 16:22:00
| null |
MILWAUKEE--(BUSINESS WIRE)--ZURN ELKAY WATER SOLUTIONS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS
|
ZURN ELKAY WATER SOLUTIONS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS
|
ZWS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-20 13:09:00
| null |
MILWAUKEE--(BUSINESS WIRE)--ZURN ELKAY WATER SOLUTIONS DECLARES QUARTERLY CASH DIVIDEND
|
ZURN ELKAY WATER SOLUTIONS DECLARES QUARTERLY CASH DIVIDEND
|
ZWS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-07-21 11:54:00
| null |
MILWAUKEE--(BUSINESS WIRE)--ZURN ELKAY WATER SOLUTIONS INCREASES QUARTERLY CASH DIVIDEND
|
ZURN ELKAY WATER SOLUTIONS INCREASES QUARTERLY CASH DIVIDEND
|
ZWS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-07-01 09:54:00
| null |
MILWAUKEE--(BUSINESS WIRE)--ZURN WATER SOLUTIONS COMPLETES COMBINATION WITH ELKAY MANUFACTURING; CREATES UNRIVALED LEADER IN SUSTAINABLE WATER SOLUTIONS
|
ZURN WATER SOLUTIONS COMPLETES COMBINATION WITH ELKAY MANUFACTURING; CREATES UNRIVALED LEADER IN SUSTAINABLE WATER SOLUTIONS
|
ZWS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-26 11:46:00
| null |
MILWAUKEE--(BUSINESS WIRE)--ZURN WATER SOLUTIONS STOCKHOLDERS PAVE WAY FOR COMBINATION WITH ELKAY MANUFACTURING
|
ZURN WATER SOLUTIONS STOCKHOLDERS PAVE WAY FOR COMBINATION WITH ELKAY MANUFACTURING
|
ZWS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-24 16:18:00
| null |
MILWAUKEE--(BUSINESS WIRE)--ZURN TO PARTICIPATE IN KEYBANC CAPITAL MARKETS' INDUSTRIALS & BASIC MATERIALS CONFERENCE
|
ZURN TO PARTICIPATE IN KEYBANC CAPITAL MARKETS' INDUSTRIALS & BASIC MATERIALS CONFERENCE
|
ZWS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-05 11:55:00
| null |
MILWAUKEE--(BUSINESS WIRE)--ZURN WATER SOLUTIONS DECLARES QUARTERLY CASH DIVIDEND
|
ZURN WATER SOLUTIONS DECLARES QUARTERLY CASH DIVIDEND
|
ZWS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-04 17:29:00
| null |
CEDARHURST, N.Y.--(BUSINESS WIRE)--KUZNICKI LAW PLLC IS INVESTIGATING THE PROPOSED MERGER OF ZURN WATER SOLUTIONS CORPORATION (“THE COMPANY”) (NYSE: ZWS) WITH ELKAY MANUFACTURING COMPANY. UNDER THE TERMS OF THE PROPOSED TRANSACTION, SHAREHOLDERS OF ZURN WILL OWN ONLY APPROXIMATELY 71% OF THE COMBINED COMPANY. IF YOU WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS REGARDING THE PROPOSED SALE, YOU MAY, WITHOUT OBLIGATION OR COST TO YOU, CONTACT US TOLL FREE AT 833-938-0905, VIA EMAIL (DK@KCLASSLAW.COM),
|
ZURN WATER INVESTOR ALERT - KUZNICKI LAW PLLC INVESTIGATES MERGER OF ZURN WATER SOLUTIONS CORPORATION - ZWS
|
ZWS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-04-08 17:13:00
| null |
NEW ORLEANS--(BUSINESS WIRE)--FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, JR., ESQ. AND THE LAW FIRM OF KAHN SWICK & FOTI, LLC (“KSF”) ARE INVESTIGATING THE PROPOSED MERGER OF ZURN WATER SOLUTIONS CORPORATION (“THE COMPANY”) (NYSE: ZWS) WITH ELKAY MANUFACTURING COMPANY. UNDER THE TERMS OF THE PROPOSED TRANSACTION, SHAREHOLDERS OF ZURN WILL OWN ONLY APPROXIMATELY 71% OF THE COMBINED COMPANY. KSF IS SEEKING TO DETERMINE WHETHER THE MERGER AND THE PROCESS THAT LED TO IT ARE ADEQUATE
|
ZURN WATER INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: KAHN SWICK & FOTI, LLC INVESTIGATES MERGER OF ZURN WATER SOLUTIONS CORPORATION - ZWS
|
ZWS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-03-02 17:03:00
| null |
NEW ORLEANS--(BUSINESS WIRE)--FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, JR., ESQ. AND THE LAW FIRM OF KAHN SWICK & FOTI, LLC (“KSF”) ARE INVESTIGATING THE PROPOSED MERGER OF ZURN WATER SOLUTIONS CORPORATION (“THE COMPANY”) (NYSE: ZWS) WITH ELKAY MANUFACTURING COMPANY. UNDER THE TERMS OF THE PROPOSED TRANSACTION, SHAREHOLDERS OF ZURN WILL OWN ONLY APPROXIMATELY 71% OF THE COMBINED COMPANY. KSF IS SEEKING TO DETERMINE WHETHER THE MERGER AND THE PROCESS THAT LED TO IT ARE ADEQUATE
|
ZURN WATER INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: KAHN SWICK & FOTI, LLC INVESTIGATES MERGER OF ZURN WATER SOLUTIONS CORPORATION - ZWS
|
ZWS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-02-27 21:03:00
| null |
PHILADELPHIA, PENNSYLVANIA--(NEWSFILE CORP. - FEBRUARY 27, 2022) - INVESTOR PROTECTION FIRM KASKELA LAW LLC ANNOUNCES THAT IS INVESTIGATING ZURN WATER SOLUTIONS CORP. ("ZURN") (NYSE: ZWS) ON BEHALF OF THE COMPANY'S STOCKHOLDERS.ON FEBRUARY 14, 2022, ZURN ANNOUNCED THAT IT HAD ENTERED INTO A DEFINITIVE AGREEMENT TO ACQUIRE ELKAY MANUFACTURING CO. ("ELKAY") IN AN ALL-STOCK TRANSACTION. ACCORDING TO THE ANNOUNCEMENT, ZURN IS EXPECTED TO ISSUE 52.5 MILLION SHARES OF ZURN COMMON STOCK TO ELKAY SHAREHOLDERS WHO...
|
INVESTIGATION ALERT: KASKELA LAW LLC ANNOUNCES STOCKHOLDER INVESTIGATION OF ZURN WATER SOLUTIONS CORP. (ZWS) IN CONNECTION WITH RECENT MERGER ANNOUNCEMENT
|
ZWS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-02-23 16:33:00
| null |
MILWAUKEE--(BUSINESS WIRE)-- #PEOPLEMAKETHEDIFFERENCE--ZURN WATER SOLUTIONS CORPORATION (NYSE: ZWS) ANNOUNCED TODAY IT WAS NAMED A 2022 TOP WORKPLACE USA BY ENERGAGE.
|
ZURN WATER SOLUTIONS NAMED A 2022 TOP WORKPLACE USA
|
ZWS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-02-22 16:31:00
| null |
MILWAUKEE--(BUSINESS WIRE)-- #SUSTAINABILITY--ZURN WATER SOLUTIONS CORPORATION (NYSE: ZWS) PUBLISHED ITS 2021 SUSTAINABILITY REPORT, WHICH IS THE FIRST REPORT AS A PURE-PLAY WATER COMPANY.
|
ZURN WATER SOLUTIONS PUBLISHES 2021 SUSTAINABILITY REPORT; LAUNCHES “WAVES” – AN EMPLOYEE-LED SOCIAL IMPACT FUND
|
ZWS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-02-16 22:52:00
| null |
NEW ORLEANS, FEB. 16, 2022 /PRNEWSWIRE/ -- FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, JR., ESQ.
|
ZURN WATER INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: KAHN SWICK & FOTI, LLC INVESTIGATES MERGER OF ZURN WATER SOLUTIONS CORPORATION - ZWS
|
ZWS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-02-15 17:10:00
| null |
WILMINGTON, DELAWARE--(NEWSFILE CORP. - FEBRUARY 15, 2022) - RIGRODSKY LAW, P.A. IS INVESTIGATING ZURN WATER SOLUTIONS CORPORATION ("ZURN") (NYSE: ZWS) REGARDING POSSIBLE BREACHES OF FIDUCIARY DUTIES AND OTHER VIOLATIONS OF LAW RELATED TO ZURN'S AGREEMENT TO MERGE WITH ELKAY MANUFACTURING COMPANY.TO LEARN MORE ABOUT THIS INVESTIGATION AND YOUR RIGHTS, VISIT: HTTPS://WWW.RL-LEGAL.COM/CASES-ZURN-WATER-SOLUTIONS-CORP.YOU MAY ALSO CONTACT SETH D. RIGRODSKY OR GINA M. SERRA COST AND OBLIGATION FREE AT (888) 969-4242 OR INFO@RL-LEGAL.COM.RIGRODSKY LAW, P.A., WITH OFFICES...
|
SHAREHOLDER ALERT: RIGRODSKY LAW, P.A. ANNOUNCES INVESTIGATION OF ZURN WATER SOLUTIONS CORPORATION MERGER
|
ZWS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-02-15 16:52:00
| null |
NEW YORK, FEB. 15, 2022 /PRNEWSWIRE/ -- WEISSLAW LLP IS INVESTIGATING POSSIBLE BREACHES OF FIDUCIARY DUTY AND OTHER VIOLATIONS OF LAW BY THE BOARD OF DIRECTORS OF ZURN WATER SOLUTIONS CORPORATION ("ZURN WATER SOLUTIONS" OR THE "COMPANY") (NYSE: ZWS), IN CONNECTION WITH THE PROPOSED MERGER OF THE COMPANY WITH ELKAY MANUFACTURING COMPANY ("ELKAY"). UNDER THE TERMS OF THE MERGER AGREEMENT, ELKAY SHAREHOLDERS WILL RECEIVE UP TO 52.5M SHARES OF ZURN WATER SOLUTIONS, WHICH WILL RESULT IN ELKAY SHAREHOLDERS OWNING APPROXIMATELY 29% OF THE COMBINED COMPANY AND CURRENT ZURN WATER SOLUTIONS SHAREHOLDERS OWNING 71% OF THE COMBINED COMPANY.
|
SHAREHOLDER ALERT: WEISSLAW LLP INVESTIGATES ZURN WATER SOLUTIONS CORPORATION
|
ZWS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-02-14 11:43:00
| null |
NEW YORK--(BUSINESS WIRE)--HALPER SADEH LLP, AN INVESTOR RIGHTS LAW FIRM, IS INVESTIGATING WHETHER THE MERGER OF ZURN WATER SOLUTIONS CORPORATION (NYSE: ZWS) AND ELKAY MANUFACTURING COMPANY IS FAIR TO ZURN WATER SHAREHOLDERS. HALPER SADEH ENCOURAGES ZURN WATER SHAREHOLDERS TO CLICK HERE TO LEARN MORE ABOUT THEIR LEGAL RIGHTS AND OPTIONS OR CONTACT DANIEL SADEH OR ZACHARY HALPER AT (212) 763-0060 OR SADEH@HALPERSADEH.COM OR ZHALPER@HALPERSADEH.COM. THE INVESTIGATION CONCERNS WHETHER ZURN WATER A
|
ZWS STOCK INVESTIGATION: HALPER SADEH LLP IS INVESTIGATING WHETHER THE MERGER OF ZURN WATER SOLUTIONS CORPORATION IS FAIR TO SHAREHOLDERS
|
ZWS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-02-14 06:31:00
| null |
MILWAUKEE--(BUSINESS WIRE)--ZURN WATER SOLUTIONS AND ELKAY MANUFACTURING TO COMBINE; CREATING A LEADER IN SUSTAINABLE WATER SOLUTIONS
|
ZURN WATER SOLUTIONS AND ELKAY MANUFACTURING TO COMBINE; CREATING A LEADER IN SUSTAINABLE WATER SOLUTIONS
|
ZWS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-02-03 12:47:00
| null |
MILWAUKEE--(BUSINESS WIRE)--ZURN WATER SOLUTIONS DECLARES QUARTERLY CASH DIVIDEND
|
ZURN WATER SOLUTIONS DECLARES QUARTERLY CASH DIVIDEND
|
ZWS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-02-01 16:08:00
| null |
MILWAUKEE--(BUSINESS WIRE)-- #EARNINGS--ZURN WATER SOLUTIONS REPORTS FOURTH QUARTER 2021 FINANCIAL RESULTS
|
ZURN WATER SOLUTIONS REPORTS FOURTH QUARTER 2021 FINANCIAL RESULTS
|
ZWS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-12-21 17:36:00
| null |
MILWAUKEE--(BUSINESS WIRE)--ZURN WATER SOLUTIONS CORPORATION (NYSE: ZWS) ANNOUNCED TODAY IT JOINED THE UNITED NATIONS GLOBAL COMPACT INITIATIVE.
|
ZURN WATER SOLUTIONS JOINS THE UNITED NATIONS GLOBAL COMPACT
|
ZWS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-12-10 16:10:00
| null |
MILWAUKEE, WIS.--(BUSINESS WIRE)--ZURN TO PARTICIPATE IN OPPENHEIMER MIDWEST INDUSTRIAL (VIRTUAL) SUMMIT
|
ZURN TO PARTICIPATE IN OPPENHEIMER MIDWEST INDUSTRIAL (VIRTUAL) SUMMIT
|
ZWS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-12-09 16:19:00
| null |
MILWAUKEE--(BUSINESS WIRE)-- #SUSTAINABILITY--ZURN WATER SOLUTIONS WAS NAMED BY NEWSWEEK AS ONE OF AMERICA'S MOST RESPONSIBLE COMPANIES 2022.
|
ZURN WATER SOLUTIONS NAMED TO NEWSWEEK'S 2022 LIST OF AMERICA'S MOST RESPONSIBLE COMPANIES
|
ZWS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-11-17 17:26:00
| null |
MILWAUKEE--(BUSINESS WIRE)--ZURN WATER SOLUTIONS CORPORATION EXPANDED ITS HIGH-QUALITY FLOW SYSTEMS PORTFOLIO WITH THE ACQUISITION OF THE WADE DRAINS PRODUCT LINE FROM MCWANE.
|
ZURN WATER SOLUTIONS EXPANDS SUSTAINABLE FLOW SYSTEMS PORTFOLIO WITH WADE DRAINS ACQUISITION
|
ZWS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-11-16 16:14:00
| null |
MILWAUKEE--(BUSINESS WIRE)--ZURN TO PARTICIPATE IN CREDIT SUISSE 9TH ANNUAL INDUSTRIALS CONFERENCE
|
ZURN TO PARTICIPATE IN CREDIT SUISSE 9TH ANNUAL INDUSTRIALS CONFERENCE
|
ZWS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-10-21 14:12:00
| null |
MILWAUKEE--(BUSINESS WIRE)--ZURN WATER SOLUTIONS INITIATES A QUARTERLY CASH DIVIDEND
|
ZURN WATER SOLUTIONS INITIATES A QUARTERLY CASH DIVIDEND
|
ZWS
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-21 06:00:00
| null |
BEIJING, JAN. 21, 2022 /PRNEWSWIRE/ -- CHINA ZENIX AUTO INTERNATIONAL LIMITED (OTC: ZXAIY) (THE "COMPANY"), ONE OF THE LARGEST COMMERCIAL VEHICLE WHEEL MANUFACTURERS IN CHINA IN BOTH THE AFTERMARKET AND OEM MARKET BY SALES VOLUME, TODAY ANNOUNCED THAT AT A GENERAL MEETING OF SHAREHOLDERS HELD TODAY, THE COMPANY'S SHAREHOLDERS VOTED IN FAVOR OF THE PROPOSAL TO AUTHORIZE AND APPROVE THE PREVIOUSLY ANNOUNCED AGREEMENT AND PLAN OF MERGER (THE "MERGER AGREEMENT") DATED OCTOBER 19, 2021 BY AND BETWEEN THE COMPANY AND NEWRACE LIMITED ("PARENT"), WHICH WAS JOINED BY NEWRACE MERGERSUB LIMITED, A WHOLLY OWNED SUBSIDIARY OF PARENT ("MERGER SUB") ON OCTOBER 20, 2021, PURSUANT TO WHICH THE MERGER SUB WILL BE MERGED WITH AND INTO THE COMPANY (THE "MERGER"), WITH THE COMPANY CONTINUING AS THE SURVIVING COMPANY AND BECOMING A WHOLLY OWNED SUBSIDIARY OF THE PARENT. APPROXIMATELY 76.1% OF THE COMPANY'S TOTAL OUTSTANDING ORDINARY SHARES WERE PRESENTED IN PERSON OR BY PROXY AT TODAY'S GENERAL MEETING.
|
ZENIX ANNOUNCES SHAREHOLDERS' APPROVAL OF MERGER AGREEMENT
|
ZXAIY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-19 09:08:00
| null |
BOSTON AND EMERYVILLE, CALIF. , OCT. 19, 2022 /PRNEWSWIRE/ -- TODAY, GINKGO BIOWORKS (NYSE: DNA), THE LEADING HORIZONTAL PLATFORM FOR CELL PROGRAMMING, AND ZYMERGEN (NASDAQ: ZY) ANNOUNCED THAT GINKGO HAS COMPLETED ITS PREVIOUSLY ANNOUNCED ACQUISITION OF ZYMERGEN.
|
GINKGO BIOWORKS COMPLETES ACQUISITION OF ZYMERGEN
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-08-24 15:55:00
| null |
NEW ORLEANS--(BUSINESS WIRE)--FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, JR., ESQ. AND THE LAW FIRM OF KAHN SWICK & FOTI, LLC (“KSF”) ARE INVESTIGATING THE PROPOSED SALE OF ZYMERGEN INC. (NASDAQGS: ZY) TO GINKGO BIOWORKS HOLDINGS, INC. (NYSE: DNA). UNDER THE TERMS OF THE PROPOSED TRANSACTION, SHAREHOLDERS OF ZYMERGEN WILL RECEIVE A FIXED EXCHANGE RATIO OF 0.9179 GINKGO SHARES FOR EACH SHARE OF ZYMERGEN THAT THEY OWN. KSF IS SEEKING TO DETERMINE WHETHER THIS CONSIDERATION AND THE
|
ZYMERGEN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF ZYMERGEN - ZY
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-08-22 09:38:00
| null |
NEW YORK , AUG. 22, 2022 /PRNEWSWIRE/ -- HALPER SADEH LLP, AN INVESTOR RIGHTS LAW FIRM, IS INVESTIGATING THE FOLLOWING COMPANIES FOR POTENTIAL VIOLATIONS OF THE FEDERAL SECURITIES LAWS AND/OR BREACHES OF FIDUCIARY DUTIES TO SHAREHOLDERS RELATING TO: HANGER, INC. (NYSE: HNGR)'S SALE TO PATIENT SQUARE CAPITAL FOR $18.75 IN CASH PER SHARE. IF YOU ARE A HANGER SHAREHOLDER, CLICK HERE TO LEARN MORE ABOUT YOUR RIGHTS AND OPTIONS.
|
SHAREHOLDER INVESTIGATION NOTICE: HALPER SADEH LLP INVESTIGATES HNGR, SBTX, IEA, ZY
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-08-11 05:10:00
| null |
NEW YORK , AUG. 11, 2022 /PRNEWSWIRE/ -- HALPER SADEH LLP, AN INVESTOR RIGHTS LAW FIRM, IS INVESTIGATING THE FOLLOWING COMPANIES FOR POTENTIAL VIOLATIONS OF THE FEDERAL SECURITIES LAWS AND/OR BREACHES OF FIDUCIARY DUTIES TO SHAREHOLDERS RELATING TO: GEMINI THERAPEUTICS, INC. (NASDAQ: GMTX)'S MERGER WITH DISC MEDICINE, INC. PRE-MERGER GEMINI SHAREHOLDERS ARE EXPECTED TO OWN APPROXIMATELY 28% OF THE COMBINED COMPANY. IF YOU ARE A GEMINI SHAREHOLDER, CLICK HERE TO LEARN MORE ABOUT YOUR RIGHTS AND OPTIONS.
|
SHAREHOLDER INVESTIGATION NOTICE: HALPER SADEH LLP INVESTIGATES GMTX, MANT, ZY, LOTZ
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-07-27 17:52:00
| null |
NEW YORK , JULY 27, 2022 /PRNEWSWIRE/ -- JUAN MONTEVERDE , FOUNDER AND MANAGING PARTNER OF THE CLASS ACTION FIRM MONTEVERDE & ASSOCIATES PC (THE "M&A CLASS ACTION FIRM"), A NATIONAL SECURITIES FIRM RATED TOP 50 IN THE 2018-2021 ISS SECURITIES CLASS ACTION SERVICES REPORT AND HEADQUARTERED AT THE EMPIRE STATE BUILDING IN NEW YORK CITY, IS INVESTIGATING ZYMERGEN INC. (ZY), RELATING TO ITS PROPOSED ACQUISITION BY GINKGO BIOWORKS HOLDINGS, INC. UNDER THE TERMS OF THE AGREEMENT, ZY SHAREHOLDERS ARE EXPECTED TO RECEIVE 0.9179 SHARES OF GINKGO COMMON STOCK PER SHARE THEY OWN. CLICK HERE FOR MORE INFORMATION: HTTPS://WWW.MONTEVERDELAW.COM/CASE/ZYMERGEN-INC.
|
INVESTOR ALERT - THE M&A CLASS ACTION FIRM ANNOUNCES THE INVESTIGATION OF ZYMERGEN INC. - ZY
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-07-26 02:45:00
| null |
NEW YORK , JULY 26, 2022 /PRNEWSWIRE/ -- HALPER SADEH LLP, AN INVESTOR RIGHTS LAW FIRM, IS INVESTIGATING THE FOLLOWING COMPANIES FOR POTENTIAL VIOLATIONS OF THE FEDERAL SECURITIES LAWS AND/OR BREACHES OF FIDUCIARY DUTIES TO SHAREHOLDERS RELATING TO: INFRASTRUCTURE & ENERGY ALTERNATIVES, INC. (NASDAQ: IEA)'S SALE TO MASTEC FOR $10.50 PER SHARE IN CASH AND 0.0483 OF A MASTEC SHARE FOR EACH IEA SHARE. IF YOU ARE AN IEA SHAREHOLDER, CLICK HERE TO LEARN MORE ABOUT YOUR RIGHTS AND OPTIONS.
|
SHAREHOLDER INVESTIGATION: HALPER SADEH LLP INVESTIGATES IEA, ZY, FLAC
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-07-25 21:15:00
| null |
NEW YORK , JULY 25, 2022 /PRNEWSWIRE/ -- WEISS LAW IS INVESTIGATING POSSIBLE BREACHES OF FIDUCIARY DUTY AND OTHER VIOLATIONS OF LAW BY THE BOARD OF DIRECTORS OF ZYMERGEN INC. ("ZYMERGEN" OR THE "COMPANY") (NASDAQ: ZY), CONNECTED WITH THE PROPOSED ACQUISITION OF THE COMPANY BY GINKGO BIOWORKS HOLDINGS, INC. ("GINKGO") (NYSE: DNA). UNDER THE TERMS OF THE MERGER AGREEMENT, THE COMPANY'S SHAREHOLDERS WILL RECEIVE 0.9179 SHARES OF GINKGO COMMON STOCK FOR EACH ZYMERGEN SHARE OWNED, REPRESENTING IMPLIED PER-SHARE MERGER CONSIDERATION OF APPROXIMATELY $2.68 BASED UPON GINKGO'S JULY 22, 2022 CLOSING PRICE OF $2.92.
|
SHAREHOLDER ALERT: WEISS LAW INVESTIGATES INFRASTRUCTURE AND ZYMERGEN INC.
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-07-25 19:26:00
| null |
NEW ORLEANS--(BUSINESS WIRE)--FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, JR., ESQ. AND THE LAW FIRM OF KAHN SWICK & FOTI, LLC (“KSF”) ARE INVESTIGATING THE PROPOSED SALE OF ZYMERGEN INC. (NASDAQGS: ZY) TO GINKGO BIOWORKS HOLDINGS, INC. (NYSE: DNA). UNDER THE TERMS OF THE PROPOSED TRANSACTION, SHAREHOLDERS OF ZYMERGEN WILL RECEIVE A FIXED EXCHANGE RATIO OF 0.9179 GINKGO SHARES FOR EACH SHARE OF ZYMERGEN THAT THEY OWN. KSF IS SEEKING TO DETERMINE WHETHER THIS CONSIDERATION AND THE
|
ZYMERGEN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF ZYMERGEN - ZY
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-07-25 10:59:00
| null |
MILWAUKEE , JULY 25, 2022 /PRNEWSWIRE/ -- ADEMI LLP IS INVESTIGATING ZYMERGEN (NASDAQ: ZY) FOR POSSIBLE BREACHES OF FIDUCIARY DUTY AND OTHER VIOLATIONS OF LAW IN ITS TRANSACTION WITH GINKGO. CLICK HERE TO LEARN HOW TO JOIN THE ACTION: HTTPS://WWW.ADEMILAW.COM/CASE/ZYMERGEN-INC-0 OR CALL GURI ADEMI TOLL-FREE AT 866-264-3995.
|
SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER ZYMERGEN INC. HAS OBTAINED A FAIR PRICE IN ITS TRANSACTION WITH GINKGO
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-07-25 08:20:00
| null |
NEW YORK--(BUSINESS WIRE)--HALPER SADEH LLP, AN INVESTOR RIGHTS LAW FIRM, IS INVESTIGATING WHETHER THE SALE OF ZYMERGEN INC. (NASDAQ: ZY) TO GINKGO BIOWORKS FOR 0.9179 GINKGO SHARES FOR EACH ZYMERGEN SHARE IS FAIR TO ZYMERGEN SHAREHOLDERS. HALPER SADEH ENCOURAGES ZYMERGEN SHAREHOLDERS TO CLICK HERE TO LEARN MORE ABOUT THEIR LEGAL RIGHTS AND OPTIONS OR CONTACT DANIEL SADEH OR ZACHARY HALPER AT (212) 763-0060 OR SADEH@HALPERSADEH.COM OR ZHALPER@HALPERSADEH.COM. THE INVESTIGATION CONCERNS WHETHER
|
ZY STOCK ALERT: HALPER SADEH LLP IS INVESTIGATING WHETHER THE SALE OF ZYMERGEN INC. IS FAIR TO SHAREHOLDERS
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-07-25 07:01:00
| null |
ACQUISITION IS EXPECTED TO ACCELERATE THE DEVELOPMENT OF GINKGO'S INNOVATIVE HORIZONTAL SYNTHETIC BIOLOGY PLATFORM EXPECT INTEGRATION OF ZYMERGEN'S COMPLEMENTARY AUTOMATION, SOFTWARE, AND DATA SCIENCE TOOLS AS WELL AS BIOLOGICAL ASSETS TO SIGNIFICANTLY ENHANCE THE CAPACITY, CAPABILITIES, AND EFFICIENCY OF GINKGO'S PLATFORM FOR ITS DIVERSE CUSTOMER BASE AND ENABLE NEW GROWTH OPPORTUNITIES ACROSS MANY END MARKETS ZYMERGEN'S CORE TECHNICAL TEAM IS EXPECTED TO HELP FILL SIGNIFICANT PLANNED HIRING BY GINKGO ACROSS ITS CELL ENGINEERING, AUTOMATION, DIGITAL TECHNOLOGY, AND DATA TEAMS, ACCELERATING SCALING EFFORTS WHILE MINIMIZING INCREMENTAL RUN-RATE OPERATING EXPENSES FOLLOWING INTEGRATION OF THE ACQUISITION GINKGO'S PLATFORM SERVES CUSTOMERS ACROSS INDUSTRIES AS AN ENABLING PLATFORM AND GINKGO WILL SUPPORT ZYMERGEN'S PLANS TO EVALUATE STRATEGIC ALTERNATIVES FOR THEIR ADVANCED MATERIALS AND DRUG DISCOVERY BUSINESSES ZYMERGEN STOCKHOLDERS WILL OWN 5.25% OF THE PRO FORMA COMBINED COMPANY FOLLOWING THE TRANSACTION BOSTON AND EMERYVILLE, CALIF. , JULY 25, 2022 /PRNEWSWIRE/ -- TODAY, GINKGO BIOWORKS (NYSE: DNA) — THE LEADING HORIZONTAL PLATFORM FOR CELL PROGRAMMING — AND THE BIOTECHNOLOGY COMPANY ZYMERGEN (NASDAQ: ZY) ANNOUNCED THEY HAVE ENTERED INTO A DEFINITIVE AGREEMENT UNDER WHICH GINKGO WILL ACQUIRE ZYMERGEN IN AN ALL-STOCK TRANSACTION THAT VALUES ZYMERGEN AT AN APPROXIMATELY $300 MILLION MARKET CAPITALIZATION.
|
GINKGO TO ACQUIRE ZYMERGEN
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-07-14 16:56:00
| null |
OCTANT DOUBLES ITS INITIAL INVESTMENT IN ZYMERGEN'S AUTOMATION TECHNOLOGY TO SIGNIFICANTLY INCREASE THE SCALE AND THROUGHPUT OF ITS DRUG DISCOVERY PLATFORM OCTANT DOUBLES ITS INITIAL INVESTMENT IN ZYMERGEN'S AUTOMATION TECHNOLOGY TO SIGNIFICANTLY INCREASE THE SCALE AND THROUGHPUT OF ITS DRUG DISCOVERY PLATFORM
|
ZYMERGEN EXPANDS AGREEMENT WITH OCTANT TO SCALE NEXT-GENERATION DRUG DISCOVERY PLATFORM
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-28 16:05:00
| null |
EMERYVILLE, CALIF., JUNE 28, 2022 (GLOBE NEWSWIRE) -- ZYMERGEN INC. (“ZYMERGEN” OR THE “COMPANY”) TODAY ANNOUNCED AN R&D SUPPLY AGREEMENT TO PROVIDE ZYMERGEN Z2TM POLYIMIDE POWDER TO 3D4MAKERS FOR USE IN HIGH PERFORMANCE 3D PRINTING APPLICATIONS. 3D4MAKERS WILL CONVERT THE POWDER TO FILAMENT, OFFERING ITS FIRST-EVER POLYIMIDE FILAMENT TO CUSTOMERS FOR USE ACROSS A WIDE RANGE OF APPLICATIONS INCLUDING AEROSPACE, AUTOMOTIVE, AND TRANSPORTATION.
|
ZYMERGEN ANNOUNCES R&D SUPPLY AGREEMENT WITH 3D4MAKERS TO PROVIDE NEW POLYIMIDE FOR USE IN HIGH-PERFORMANCE 3D PRINTING APPLICATIONS
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-26 16:05:00
| null |
EMERYVILLE, CALIF., MAY 26, 2022 (GLOBE NEWSWIRE) -- ZYMERGEN INC. (“ZYMERGEN” OR THE “COMPANY”), TODAY ANNOUNCED IT HAS ENTERED INTO AN AGREEMENT WITH OCTANT FOR THE SALE OF A MODULAR AUTOMATION SYSTEM TO SCALE OCTANT'S NEXT-GENERATION PLATFORM TO DEVELOP BREAKTHROUGH MEDICINES.
|
ZYMERGEN SELLS MODULAR AUTOMATION SYSTEM TO OCTANT TO SCALE NEXT-GENERATION DRUG DISCOVERY PLATFORM
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-12 16:05:00
| null |
EMERYVILLE, CALIF., MAY 12, 2022 (GLOBE NEWSWIRE) -- BIOTECHNOLOGY COMPANY ZYMERGEN INC. (“ZYMERGEN” OR THE “COMPANY”), TODAY REPORTED PRELIMINARY FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2022.
|
ZYMERGEN REPORTS PRELIMINARY FIRST QUARTER 2022 FINANCIAL RESULTS
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-04-29 08:00:00
| null |
EMERYVILLE, CALIF., APRIL 29, 2022 (GLOBE NEWSWIRE) -- ZYMERGEN INC. (“ZYMERGEN” OR THE “COMPANY”), TODAY ANNOUNCED THE COMPANY WILL BE PARTICIPATING IN THE UPCOMING BOFA SECURITIES 2022 HEALTHCARE CONFERENCE HELD IN LAS VEGAS, NV.
|
ZYMERGEN TO PARTICIPATE IN THE BOFA SECURITIES 2022 HEALTHCARE CONFERENCE
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-03-22 16:05:00
| null |
EMERYVILLE, CALIF., MARCH 22, 2022 (GLOBE NEWSWIRE) -- BIOTECHNOLOGY COMPANY ZYMERGEN INC. (“ZYMERGEN” OR THE “COMPANY”), TODAY REPORTED PRELIMINARY FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2021.
|
ZYMERGEN REPORTS PRELIMINARY FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-03-06 19:00:00
| null |
EMERYVILLE, CALIF., MARCH 06, 2022 (GLOBE NEWSWIRE) -- BIOTECHNOLOGY COMPANY ZYMERGEN (ZY) IS PLEASED TO ANNOUNCE EARLY RESULTS FROM ITS WORK ON INFECTIOUS DISEASE, DISCOVERING HUNDREDS OF POTENTIAL NOVEL HITS AGAINST MALARIA, TUBERCULOSIS, AND COVID-19 TARGETS. HITS FOR PFAPP, A CRITICAL TARGET IN THE TREATMENT OF MALARIA, ARE NOW BEING ADVANCED FOR VALIDATION, WITH HITS FOR AN EMERGING COVID-19 TARGET, PLPRO, EXPECTED TO FOLLOW.
|
ZYMERGEN ADVANCES MOLECULES FOR PROMINENT MALARIA AND COVID-19 DRUG TARGETS FOR FURTHER TESTING
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-10 20:17:00
| null |
DELIVERING PLATFORM EXPERTISE AND DEVELOPING NOVEL MICROBES, MOLECULES AND MATERIALS FOR CUSTOMERS ACROSS A VARIETY OF MARKETS DELIVERING PLATFORM EXPERTISE AND DEVELOPING NOVEL MICROBES, MOLECULES AND MATERIALS FOR CUSTOMERS ACROSS A VARIETY OF MARKETS
|
ZYMERGEN DEBUTS AUTOMATION BUSINESS AND SHARES PROGRAM PORTFOLIO AT 40TH ANNUAL JP MORGAN HEALTHCARE CONFERENCE
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-09 21:00:00
| null |
EXPLORING NATURAL PRODUCTS FOR INNOVATIVE THERAPEUTICS EXPLORING NATURAL PRODUCTS FOR INNOVATIVE THERAPEUTICS
|
ZYMERGEN ANNOUNCES EMERGING DRUG DISCOVERY BUSINESS ENABLED BY ONE OF THE WORLD'S LARGEST METAGENOMICS DATABASES AND PROPRIETARY SYNTHETIC BIOLOGY PLATFORM
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-12-03 21:00:00
| null |
NEW YORK--(BUSINESS WIRE)-- #SECURITIES--BRAGAR EAGEL & SQUIRE, P.C., A NATIONALLY RECOGNIZED SHAREHOLDER RIGHTS LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST ZYMERGEN INC. (NASDAQ: ZY) ON BEHALF OF LONG-TERM STOCKHOLDERS FOLLOWING A CLASS ACTION COMPLAINT THAT WAS FILED AGAINST SEQUENTIAL ON AUGUST 4, 2021. OUR INVESTIGATION CONCERNS WHETHER THE BOARD OF DIRECTORS OF SEQUENTIAL HAVE BREACHED THEIR FIDUCIARY DUTIES TO THE COMPANY. THE COMPLAINT ALLEGES THAT THE REGISTRATION STATEMENT WAS MATERIALLY
|
ZYMERGEN ALERT: BRAGAR EAGEL & SQUIRE, P.C. IS INVESTIGATING ZYMERGEN INC. ON BEHALF OF LONG-TERM STOCKHOLDERS AND ENCOURAGES INVESTORS TO CONTACT THE FIRM
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-11-11 12:00:00
| null |
LOS ANGELES--(BUSINESS WIRE)---- $ZY #INVESTORS--THE LAW OFFICES OF FRANK R. CRUZ ANNOUNCES INVESTIGATION OF ZYMERGEN INC. (ZY) ON BEHALF OF INVESTORS
|
THE LAW OFFICES OF FRANK R. CRUZ ANNOUNCES INVESTIGATION OF ZYMERGEN INC. (ZY) ON BEHALF OF INVESTORS
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-11-10 17:31:00
| null |
LOS ANGELES--(BUSINESS WIRE)--GLANCY PRONGAY & MURRAY LLP (“GPM”), A LEADING NATIONAL SHAREHOLDER RIGHTS LAW FIRM, TODAY ANNOUNCES THAT IT HAS COMMENCED AN INVESTIGATION OF POTENTIAL CLAIMS AGAINST THE BOARD OF DIRECTORS OF ZYMERGEN INC. (“ZYMERGEN” OR THE “COMPANY”) (NASDAQ: ZY) CONCERNING WHETHER THE BOARD OF DIRECTORS BREACHED ITS FIDUCIARY DUTIES TO ZYMERGEN SHAREHOLDERS. IF YOU STILL HOLD ZYMERGEN SHARES THAT WERE PURCHASED PURSUANT TO OR AROUND THE TIME OF THE APRIL 2021 IPO AND WISH
|
GLANCY PRONGAY & MURRAY LLP, A LEADING SECURITIES FRAUD LAW FIRM, ANNOUNCES INVESTIGATION OF ZYMERGEN INC. (ZY) ON BEHALF OF INVESTORS
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-10-04 12:35:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - OCTOBER 4, 2021) - THE KLEIN LAW FIRM ANNOUNCES THAT A CLASS ACTION COMPLAINT HAS BEEN FILED ON BEHALF OF SHAREHOLDERS OF ZYMERGEN INC. (NASDAQ: ZY) ALLEGING THAT THE COMPANY VIOLATED FEDERAL SECURITIES LAWS.THIS LAWSUIT IS ON BEHALF OF INVESTORS WHO PURCHASED ZY COMMON STOCK PURSUANT AND/OR TRACEABLE TO THE DOCUMENTS ISSUED IN CONNECTION WITH THE COMPANY'S APRIL 2021 INITIAL PUBLIC OFFERING.LEAD PLAINTIFF DEADLINE: OCTOBER 4, 2021NO OBLIGATION OR...
|
ZY ALERT: THE KLEIN LAW FIRM ANNOUNCES A LEAD PLAINTIFF DEADLINE OF OCTOBER 4, 2021 IN THE CLASS ACTION FILED ON BEHALF OF ZYMERGEN INC. LIMITED SHAREHOLDERS
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-10-04 10:00:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - OCTOBER 4, 2021) - BRONSTEIN, GEWIRTZ & GROSSMAN, LLC NOTIFIES INVESTORS THAT A CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST ZYMERGEN, INC. ("ZYMERGEN" OR THE "COMPANY") (NASDAQ: ZY) AND CERTAIN OF ITS OFFICERS, ON BEHALF OF SHAREHOLDERS WHO PURCHASED OR OTHERWISE ACQUIRED ZYMERGEN COMMON STOCK PURSUANT AND/OR TRACEABLE TO THE REGISTRATION STATEMENT AND PROSPECTUS (COLLECTIVELY, THE "REGISTRATION STATEMENT") ISSUED IN CONNECTION WITH THE COMPANY'S APRIL 2021 INITIAL PUBLIC...
|
LAST FEW HOURS FOR SHAREHOLDERS TO ACTIVELY PARTICIPATE IN ZYMERGEN, INC. (ZY) CLASS ACTION: BRONSTEIN, GEWIRTZ & GROSSMAN, LLC
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-10-04 05:26:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - OCTOBER 4, 2021) - THE FOLLOWING STATEMENT IS BEING ISSUED BY LEVI & KORSINSKY, LLP:TO: ALL PERSONS OR ENTITIES WHO PURCHASED OR OTHERWISE ACQUIRED SECURITIES OF ZYMERGEN INC. (NASDAQ: ZY) ("ZYMERGEN") THIS LAWSUIT IS ON BEHALF OF INVESTORS WHO PURCHASED ZY COMMON STOCK PURSUANT AND/OR TRACEABLE TO THE DOCUMENTS ISSUED IN CONNECTION WITH THE COMPANY'S APRIL 2021 INITIAL PUBLIC OFFERING.. YOU ARE HEREBY NOTIFIED THAT A SECURITIES CLASS ACTION LAWSUIT HAS...
|
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP NOTIFIES SHAREHOLDERS OF ZYMERGEN INC. OF A CLASS ACTION LAWSUIT AND A LEAD PLAINTIFF DEADLINE OF OCTOBER 4, 2021 - ZY
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-10-03 12:00:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - OCTOBER 3, 2021) - WHY: NEW YORK, N.Y., OCTOBER 3, 2021. ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, REMINDS PURCHASERS OF THE SECURITIES OF ZYMERGEN INC. (NASDAQ: ZY) PURSUANT AND/OR TRACEABLE TO THE REGISTRATION STATEMENT AND RELATED PROSPECTUS (COLLECTIVELY, THE "REGISTRATION STATEMENT") ISSUED IN CONNECTION WITH ZYMERGEN'S APRIL 2021 INITIAL PUBLIC OFFERING (THE "IPO"), OF THE IMPORTANT OCTOBER 4, 2021 LEAD PLAINTIFF DEADLINE.SO WHAT: IF YOU PURCHASED...
|
ZY FINAL DEADLINE TOMORROW: ROSEN, A TOP RANKED LAW FIRM, ENCOURAGES ZYMERGEN INC. INVESTORS WITH LOSSES TO SECURE COUNSEL BEFORE IMPORTANT MONDAY DEADLINE IN SECURITIES CLASS ACTION - ZY
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-10-03 11:11:00
| null |
RADNOR, PENNSYLVANIA--(NEWSFILE CORP. - OCTOBER 3, 2021) - THE LAW FIRM OF KESSLER TOPAZ MELTZER & CHECK, LLP REMINDS INVESTORS OF LEAD PLAINTIFF DEADLINE IN SECURITIES FRAUD CLASS ACTION LAWSUIT FILED AGAINST ZYMERGEN INC. (NASDAQ: ZY) ("ZYMERGEN") ON BEHALF OF THOSE WHO PURCHASED OR ACQUIRED ZYMERGEN COMMON STOCK PURSUANT AND/OR TRACEABLE TO THE REGISTRATION STATEMENT AND PROSPECTUS (COLLECTIVELY, THE "REGISTRATION STATEMENT") ISSUED IN CONNECTION WITH ZYMERGEN'S APRIL 2021 INITIAL PUBLIC OFFERING ("IPO").DEADLINE REMINDER: ...
|
KESSLER TOPAZ MELTZER & CHECKER, LLP: FINAL DEADLINE REMINDER FOR ZYMERGEN INC. INVESTORS - ZY
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-10-01 18:30:00
| null |
SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES EXCEEDING $50,000 IN ZYMERGEN TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONSNEW YORK, NEW YORK--(NEWSFILE CORP. - OCTOBER 1, 2021) - FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST ZYMERGEN INC. ("ZYMERGEN" OR THE "COMPANY") (NASDAQ: ZY) AND REMINDS INVESTORS OF THE OCTOBER 4, 2021 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY. IF YOU SUFFERED LOSSES EXCEEDING $50,000 INVESTING IN ZYMERGEN STOCK OR OPTIONS BETWEEN...
|
ZYMERGEN SHAREHOLDER ALERT
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-10-01 16:30:00
| null |
BOSTON, MASSACHUSETTS--(NEWSFILE CORP. - OCTOBER 1, 2021) - THE THORNTON LAW FIRM ALERTS INVESTORS WHO PURCHASED ZYMERGEN INC. COMMON STOCK (NASDAQ: ZY) PURSUANT OR TRACEABLE TO THE REGISTRATION STATEMENT AND PROSPECTUS ISSUED IN CONNECTION WITH THE COMPANY'S APRIL 2021 INITIAL PUBLIC OFFERING MAY SEEK TO PARTICIPATE IN THE CASE AS A LEAD PLAINTIFF. INTERESTED INVESTORS MAY CONTACT THE THORNTON LAW FIRM'S INVESTOR PROTECTION TEAM BY VISITING WWW.TENLAW.COM/CASES/ZYMERGEN FOR MORE INFORMATION. INVESTORS MAY ALSO EMAIL...
|
ZY INVESTOR ALERT: SHAREHOLDER LAWSUIT DEADLINE APPROACHING
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-10-01 15:15:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - OCTOBER 1, 2021) - WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, REMINDS PURCHASERS OF THE SECURITIES OF ZYMERGEN INC. (NASDAQ: ZY) PURSUANT AND/OR TRACEABLE TO THE REGISTRATION STATEMENT AND RELATED PROSPECTUS (COLLECTIVELY, THE "REGISTRATION STATEMENT") ISSUED IN CONNECTION WITH ZYMERGEN'S APRIL 2021 INITIAL PUBLIC OFFERING (THE "IPO"), OF THE IMPORTANT OCTOBER 4, 2021 LEAD PLAINTIFF DEADLINE.SO WHAT: IF YOU PURCHASED ZYMERGEN SECURITIES PURSUANT AND/OR TRACEABLE TO...
|
ZY FINAL DEADLINE MONDAY: ROSEN, TRUSTED INVESTOR COUNSEL, ENCOURAGES ZYMERGEN INC. INVESTORS WITH LOSSES IN EXCESS OF $100K SECURE COUNSEL BEFORE IMPORTANT OCTOBER 4 DEADLINE IN SECURITIES CLASS ACTION - ZY
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-10-01 14:21:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - OCTOBER 1, 2021) - POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZYMERGEN, INC. ("ZYMERGEN OR THE "COMPANY") (NASDAQ: ZY). SUCH INVESTORS ARE ADVISED TO CONTACT ROBERT S. WILLOUGHBY AT NEWACTION@POMLAW.COM OR 888-476-6529, EXT. 7980.THE INVESTIGATION CONCERNS WHETHER ZYMERGEN AND CERTAIN OF ITS OFFICERS AND/OR DIRECTORS HAVE ENGAGED IN SECURITIES FRAUD OR OTHER UNLAWFUL BUSINESS PRACTICES. [CLICK HERE FOR INFORMATION ABOUT JOINING THE...
|
SHAREHOLDER ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ZYMERGEN, INC. - ZY
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-10-01 12:35:00
| null |
LOS ANGELES--(BUSINESS WIRE)---- $ZY #INVESTORS--THE LAW OFFICES OF FRANK R. CRUZ REMINDS INVESTORS OF LOOMING DEADLINE IN THE CLASS ACTION LAWSUIT AGAINST ZYMERGEN INC. (ZY)
|
THE LAW OFFICES OF FRANK R. CRUZ REMINDS INVESTORS OF LOOMING DEADLINE IN THE CLASS ACTION LAWSUIT AGAINST ZYMERGEN INC. (ZY)
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-10-01 12:00:00
| null |
NEW YORK, NY / ACCESSWIRE / OCTOBER 1, 2021 / THE LAW OFFICES OF VINCENT WONG ANNOUNCE THAT CLASS ACTIONS HAVE COMMENCED ON BEHALF OF CERTAIN SHAREHOLDERS IN THE FOLLOWING COMPANIES. IF YOU SUFFERED A LOSS YOU HAVE UNTIL THE LEAD PLAINTIFF DEADLINE TO REQUEST THAT THE COURT APPOINT YOU AS LEAD PLAINTIFF.
|
SHAREHOLDER ALERT: ATVI ZY VIEW: THE LAW OFFICES OF VINCENT WONG REMINDS INVESTORS OF IMPORTANT CLASS ACTION DEADLINES
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-10-01 11:00:00
| null |
NEW YORK--(BUSINESS WIRE)--ATTORNEY ADVERTISING--BRONSTEIN, GEWIRTZ & GROSSMAN, LLC NOTIFIES INVESTORS THAT A CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST ZYMERGEN, INC. ("ZYMERGEN” OR THE "COMPANY") (NASDAQ: ZY) AND CERTAIN OF ITS OFFICERS, ON BEHALF OF SHAREHOLDERS WHO PURCHASED OR OTHERWISE ACQUIRED ZYMERGEN COMMON STOCK PURSUANT AND/OR TRACEABLE TO THE REGISTRATION STATEMENT AND PROSPECTUS (COLLECTIVELY, THE "REGISTRATION STATEMENT") ISSUED IN CONNECTION WITH THE COMPANY'S APRIL 2021 INI
|
MONDAY DEADLINE FOR SHAREHOLDERS TO ACTIVELY PARTICIPATE IN ZYMERGEN, INC. (ZY) CLASS ACTION: BRONSTEIN, GEWIRTZ & GROSSMAN, LLC
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-30 15:08:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 30, 2021) - THE KLEIN LAW FIRM ANNOUNCES THAT A CLASS ACTION COMPLAINT HAS BEEN FILED ON BEHALF OF SHAREHOLDERS OF ZYMERGEN INC. (NASDAQ: ZY) ALLEGING THAT THE COMPANY VIOLATED FEDERAL SECURITIES LAWS.THIS LAWSUIT IS ON BEHALF OF INVESTORS WHO PURCHASED ZY COMMON STOCK PURSUANT AND/OR TRACEABLE TO THE DOCUMENTS ISSUED IN CONNECTION WITH THE COMPANY'S APRIL 2021 INITIAL PUBLIC OFFERING.LEAD PLAINTIFF DEADLINE: OCTOBER 4, 2021NO OBLIGATION OR...
|
ZY ALERT: THE KLEIN LAW FIRM ANNOUNCES A LEAD PLAINTIFF DEADLINE OF OCTOBER 4, 2021 IN THE CLASS ACTION FILED ON BEHALF OF ZYMERGEN INC. LIMITED SHAREHOLDERS
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-30 13:15:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 30, 2021) - JAKUBOWITZ LAW ANNOUNCES THAT A SECURITIES FRAUD CLASS ACTION LAWSUIT HAS COMMENCED ON BEHALF OF SHAREHOLDERS OF ZYMERGEN INC. (NASDAQ: ZY).CLICK HERE FOR MORE DETAILS:HTTPS://CLAIMYOURLOSS.COM/SECURITIES/ZYMERGEN-INC-LOSS-SUBMISSION-FORM/?ID=20010&FROM=5
|
ZY LAWSUIT FILED: JAKUBOWITZ LAW PURSUES CLAIMS ON BEHALF OF ZYMERGEN INC. SHAREHOLDERS
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-30 11:34:00
| null |
RADNOR, PA.--(BUSINESS WIRE)---- $ZY--KESSLER TOPAZ MELTZER & CHECK, LLP: IMPORTANT DEADLINE REMINDER FOR ZYMERGEN INC. INVESTORS IN SECURITIES FRAUD CLASS ACTION LAWSUIT
|
KESSLER TOPAZ MELTZER & CHECK, LLP: IMPORTANT DEADLINE REMINDER FOR ZYMERGEN INC. INVESTORS IN SECURITIES FRAUD CLASS ACTION LAWSUIT
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-30 09:51:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 30, 2021) - THE SECURITIES LITIGATION LAW FIRM OF THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE ON BEHALF OF SHAREHOLDERS OF ZYMERGEN INC. (NASDAQ: ZY).SHAREHOLDERS WHO PURCHASED SHARES OF ZY DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENT. APPOINTMENT AS LEAD PLAINTIFF IS NOT REQUIRED TO PARTAKE IN ANY RECOVERY.CONTACT US HERE:HTTPS://SECURITIESCLASSLAW.COM/SECURITIES/ZYMERGEN-INC-LOSS-SUBMISSION-FORM/?ID=20002&FROM=5
|
SHAREHOLDER ALERT: THE GROSS LAW FIRM NOTIFIES SHAREHOLDERS OF ZYMERGEN INC. OF A CLASS ACTION LAWSUIT AND A LEAD PLAINTIFF DEADLINE OF OCTOBER 4, 2021 - (ZY)
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.